Drugs / ABBV-1758
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07599670 | May 2026 → Apr 2030 expected | Alzheimer disease | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-1758 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07599670 ↗ |
| Route | Intravenous | “Intravenous (IV) or Subcutaneous (SC)” NCT07599670 ↗ |
| Route | Subcutaneous | “Intravenous (IV) or Subcutaneous (SC)” NCT07599670 ↗ |